Green leaf pharmaceutical LPM4870108 tablets were approved for clinical trials in China.

Guide: This product can be used to treat patients with NTRK fusion-positive cancer of different tumor types and to prevent the production of first-generation NTRK inhibitors.
27, Greenlee Pharmaceuticals announced that its group had approved the launch of clinical trials by the Drug Review Center ("CDE") of the State Drug Administration of the People's Republic of China ("China") for the first time the synthesis of LPM4870108 tablets ("LY 01018"), a new class 1 NTRK small molecule inhibitor with independent intellectual property rights.
can be used to treat patients with NTRK fusion-positive cancers of different tumor types and to prevent the production of first-generation NTRK inhibitors.
NTRK gene fusion is a clear and definitive carcinogenic driver, including lung cancer, colorectal cancer, thyroid tumor, fibroblastoma and other 20th generation NTRK target has been listed products, patients after a period of treatment, most of the obtained mutations, including NTRK1 -G595R, NTRK2 -G639R, NTRK3 -G 623R and so on.
has not yet been approved for the above mutation of the second generation of inhibitors on the market.
LPM4870108 is a highly selective second generation NTRK inhibitor found by the Group to be effective for both wild and approved mutations, and is intended to treat "NTRK gene fusion and its drug-resistant mutation-positive solid tumor patients."
listed the first generation of target products with all the relevant adaptations, but also covers the first generation of inhibitors congenitally inhibited or after the use of winning resistance to drug treatment of patients, that is, including NTRK gene fusion solid tumor patients first- and second-line treatment of diseases, the scope of adaptation is more extensive.
.